Martine Piccart

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

Adjuvant Olaparib for Patients with <i>BRCA1</i> - or <i>BRCA2</i> -Mutated Breast Cancer

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial